IPSC · Century Therapeutics Inc. Common Stock
View on chartInsiders & Stakes
| Versant Venture Capital VI, L.P. 10% Owner | ▼ Sell | Other | 11,452,014 Shares held | 8/9/2022 | View profile |
| Brent Pfeiffenberger President and CEO | ▼ Sell | Tax Withholding | 3,633,839 Shares held | 9/11/2026 | View profile |
| Chad Cowan Chief Scientific Officer | ▼ Sell | Tax Withholding | 1,175,322 Shares held | 6/11/2026 | View profile |
| Gregory Russotti See Remarks | ▼ Sell | Open Market | 509,198 Shares held | 9/14/2026 | View profile |
| Douglas Carr SVP Finance & Operations | ▼ Sell | Open Market | 502,907 Shares held | 9/14/2026 | View profile |
| Borges Luis Chief Scientific Officer | ▲ Buy | Option Exercise | 256,535 Shares held | 4/3/2023 | View profile |
| Diem Michael Craig Chief Business Officer | ▼ Sell | Tax Withholding | 253,533 Shares held | 11/1/2023 | View profile |
| Farid Adrienne Chief Operations Officer | ▼ Sell | Open Market | 250,141 Shares held | 6/9/2025 | View profile |
| Conn Morgan Chief Finanical Officer | ▲ Buy | Grant | 79,648 Shares held | 3/11/2025 | View profile |
| Levitsky Hyam President of R&D | ▲ Buy | Grant | 24,000 Shares held | 3/7/2024 | View profile |
| Quimi Daphne Director | ▲ Buy | Open Market | 5,000 Shares held | 9/12/2024 | View profile |
Transaction History
| Gregory Russotti | ▼ Sell | Open Market | 2,587 | $5K | 9/14/2026 |
| Douglas Carr | ▼ Sell | Open Market | 1,658 | $3K | 9/14/2026 |
| Brent Pfeiffenberger | ▼ Sell | Tax Withholding | 13,850 | $27K | 9/11/2026 |
| Gregory Russotti | ▼ Sell | Open Market | 534 | $1K | 9/8/2026 |
| Douglas Carr | ▼ Sell | Open Market | 254 | $521 | 9/8/2026 |
| Brent Pfeiffenberger | ▼ Sell | Tax Withholding | 463 | $977 | 9/4/2026 |
| Brent Pfeiffenberger | ▼ Sell | Tax Withholding | 31,172 | $60K | 8/14/2026 |
| Douglas Carr | ▼ Sell | Open Market | 275 | $544 | 8/3/2026 |
| Gregory Russotti | ▼ Sell | Open Market | 2,584 | $6K | 6/12/2026 |
| Douglas Carr | ▼ Sell | Open Market | 1,654 | $4K | 6/12/2026 |
| Brent Pfeiffenberger | ▼ Sell | Tax Withholding | 13,849 | $31K | 6/11/2026 |
| Chad Cowan | ▼ Sell | Tax Withholding | 358 | $802 | 6/11/2026 |
| Gregory Russotti | ▼ Sell | Open Market | 524 | $1K | 6/8/2026 |
| Douglas Carr | ▼ Sell | Open Market | 249 | $526 | 6/8/2026 |
| Brent Pfeiffenberger | ▼ Sell | Tax Withholding | 463 | $986 | 6/5/2026 |
| Brent Pfeiffenberger | ▼ Sell | Tax Withholding | 31,172 | $73K | 5/15/2026 |
| Douglas Carr | ▼ Sell | Open Market | 264 | $618 | 5/4/2026 |
| Chad Cowan | ▼ Sell | Tax Withholding | 1,365 | $3K | 4/1/2026 |
| Douglas Carr | ▼ Sell | Open Market | 7,043 | $18K | 3/12/2026 |
| Gregory Russotti | ▼ Sell | Open Market | 10,076 | $26K | 3/12/2026 |
| Brent Pfeiffenberger | ▼ Sell | Tax Withholding | 55,397 | $151K | 3/11/2026 |
| Chad Cowan | ▼ Sell | Tax Withholding | 1,431 | $4K | 3/11/2026 |
| Gregory Russotti | ▼ Sell | Open Market | 479 | $1K | 3/9/2026 |
| Douglas Carr | ▼ Sell | Open Market | 247 | $626 | 3/9/2026 |
| Brent Pfeiffenberger | ▼ Sell | Tax Withholding | 463 | $1K | 3/6/2026 |
| Brent Pfeiffenberger | ▼ Sell | Tax Withholding | 31,172 | $55K | 2/13/2026 |
| Douglas Carr | ▼ Sell | Open Market | 323 | $589 | 2/3/2026 |
| Brent Pfeiffenberger | ▲ Buy | Grant | 475,000 | $0 | 2/2/2026 |
| Gregory Russotti | ▲ Buy | Grant | 135,000 | $0 | 2/2/2026 |
| Chad Cowan | ▲ Buy | Grant | 135,000 | $0 | 2/2/2026 |
| Douglas Carr | ▲ Buy | Grant | 110,000 | $0 | 2/2/2026 |
| Chad Cowan | ▼ Sell | Tax Withholding | 1,611 | $2K | 1/2/2026 |
| Chad Cowan | ▲ Buy | Open Market | 58,060 | $49K | 12/22/2025 |
| Brent Pfeiffenberger | ▲ Buy | Open Market | 52,000 | $30K | 12/12/2025 |
| Brent Pfeiffenberger | ▼ Sell | Tax Withholding | 463 | $244 | 12/10/2025 |
| Douglas Carr | ▼ Sell | Open Market | 257 | $137 | 12/8/2025 |
| Gregory Russotti | ▼ Sell | Open Market | 526 | $280 | 12/8/2025 |
| Chad Cowan | ▼ Sell | Open Market | 5,462 | $3K | 11/20/2025 |
| Brent Pfeiffenberger | ▲ Buy | Open Market | 35,000 | $17K | 11/19/2025 |
| Brent Pfeiffenberger | ▼ Sell | Open Market | 32,456 | $15K | 11/17/2025 |
| Douglas Carr | ▼ Sell | Open Market | 292 | $171 | 11/3/2025 |
| Chad Cowan | ▲ Buy | Grant | 762,543 | $0 | 9/18/2025 |
| Douglas Carr | ▼ Sell | Open Market | 263 | $132 | 9/8/2025 |
| Brent Pfeiffenberger | ▼ Sell | Open Market | 488 | $244 | 9/8/2025 |
| Gregory Russotti | ▼ Sell | Open Market | 539 | $270 | 9/8/2025 |
| Brent Pfeiffenberger | ▲ Buy | Grant | 1,587,614 | $0 | 8/14/2025 |
| Douglas Carr | ▼ Sell | Open Market | 296 | $158 | 8/4/2025 |
| Douglas Carr | ▼ Sell | Open Market | 4,904 | $3K | 6/9/2025 |
| Farid Adrienne | ▼ Sell | Open Market | 552 | $343 | 6/9/2025 |
| Brent Pfeiffenberger | ▼ Sell | Open Market | 475 | $295 | 6/9/2025 |
| Gregory Russotti | ▼ Sell | Open Market | 526 | $327 | 6/9/2025 |
| Brent Pfeiffenberger | ▼ Sell | Open Market | 29,552 | $16K | 5/16/2025 |
| Farid Adrienne | ▼ Sell | Open Market | 1,024 | $563 | 5/5/2025 |
| Douglas Carr | ▼ Sell | Open Market | 295 | $162 | 5/5/2025 |
| Conn Morgan | ▲ Buy | Grant | 19,500 | $0 | 3/11/2025 |
| Chad Cowan | ▲ Buy | Grant | 19,500 | $0 | 3/11/2025 |
| Brent Pfeiffenberger | ▲ Buy | Grant | 521,500 | $0 | 3/11/2025 |
| Gregory Russotti | ▲ Buy | Grant | 120,000 | $0 | 3/11/2025 |
| Farid Adrienne | ▲ Buy | Grant | 120,000 | $0 | 3/11/2025 |
| Douglas Carr | ▲ Buy | Grant | 95,625 | $0 | 3/11/2025 |
| Brent Pfeiffenberger | ▼ Sell | Open Market | 2,235 | $1K | 3/10/2025 |
| Gregory Russotti | ▼ Sell | Open Market | 2,360 | $1K | 3/10/2025 |
| Farid Adrienne | ▼ Sell | Open Market | 2,359 | $1K | 3/10/2025 |
| Douglas Carr | ▼ Sell | Open Market | 1,240 | $763 | 3/10/2025 |
| Brent Pfeiffenberger | ▼ Sell | Open Market | 34,712 | $27K | 2/18/2025 |
| Farid Adrienne | ▼ Sell | Open Market | 1,054 | $822 | 2/3/2025 |
| Douglas Carr | ▼ Sell | Open Market | 351 | $274 | 2/3/2025 |
| Brent Pfeiffenberger | ▼ Sell | Tax Withholding | 243,447 | $351K | 12/4/2024 |
| Farid Adrienne | ▼ Sell | Open Market | 1,033 | $1K | 11/4/2024 |
| Douglas Carr | ▼ Sell | Open Market | 283 | $347 | 11/4/2024 |
| Douglas Carr | ▼ Sell | Tax Withholding | 16,611 | $21K | 11/1/2024 |
| Conn Morgan | ▲ Buy | Grant | 60,148 | $0 | 10/14/2024 |
| Chad Cowan | ▲ Buy | Grant | 74,376 | $0 | 10/1/2024 |
| Quimi Daphne | ▲ Buy | Open Market | 5,000 | $8K | 9/12/2024 |
| Farid Adrienne | ▼ Sell | Open Market | 1,073 | $2K | 8/5/2024 |
| Douglas Carr | ▼ Sell | Open Market | 289 | $528 | 8/5/2024 |
| Gregory Russotti | ▼ Sell | Open Market | 586 | $1K | 7/26/2024 |
| Gregory Russotti | ▼ Sell | Open Market | 1,600 | $4K | 7/24/2024 |
| Gregory Russotti | ▼ Sell | Open Market | 200 | $500 | 7/23/2024 |
| Gregory Russotti | ▼ Sell | Open Market | 5,000 | $14K | 6/20/2024 |
| Douglas Carr | ▲ Buy | Grant | 17,007 | $0 | 6/7/2024 |
| Gregory Russotti | ▼ Sell | Open Market | 5,000 | $15K | 6/5/2024 |
| Gregory Russotti | ▼ Sell | Open Market | 5,000 | $15K | 5/20/2024 |
| Gregory Russotti | ▼ Sell | Open Market | 5,000 | $16K | 5/6/2024 |
| Douglas Carr | ▼ Sell | Open Market | 257 | $798 | 5/3/2024 |
| Farid Adrienne | ▼ Sell | Open Market | 913 | $3K | 5/3/2024 |
| Gregory Russotti | ▼ Sell | Open Market | 5,000 | $15K | 4/22/2024 |
| Brent Pfeiffenberger | ▲ Buy | Grant | 17,425 | $0 | 3/7/2024 |
| Douglas Carr | ▲ Buy | Grant | 14,000 | $0 | 3/7/2024 |
| Gregory Russotti | ▲ Buy | Grant | 24,000 | $0 | 3/7/2024 |
| Farid Adrienne | ▲ Buy | Option Exercise | 22,831 | $24K | 3/7/2024 |
| Farid Adrienne | ▼ Sell | Open Market | 22,831 | $117K | 3/7/2024 |
| Farid Adrienne | ▲ Buy | Grant | 24,000 | $0 | 3/7/2024 |
| Levitsky Hyam | ▲ Buy | Grant | 24,000 | $0 | 3/7/2024 |
| Farid Adrienne | ▲ Buy | Option Exercise | 30,684 | $32K | 3/6/2024 |
| Farid Adrienne | ▼ Sell | Open Market | 30,684 | $152K | 3/6/2024 |
| Farid Adrienne | ▲ Buy | Option Exercise | 485 | $500 | 2/16/2024 |
| Farid Adrienne | ▼ Sell | Open Market | 485 | $2K | 2/16/2024 |
| Douglas Carr | ▼ Sell | Open Market | 557 | $2K | 2/6/2024 |
| Farid Adrienne | ▼ Sell | Open Market | 1,784 | $8K | 2/6/2024 |
| Farid Adrienne | ▼ Sell | Open Market | 2,035 | $8K | 2/5/2024 |
| Douglas Carr | ▼ Sell | Open Market | 643 | $2K | 2/5/2024 |
| Brent Pfeiffenberger | ▲ Buy | Grant | 279,504 | $0 | 12/4/2023 |
| Brent Pfeiffenberger | ▲ Buy | Grant | 1,173,775 | $0 | 12/4/2023 |
| Douglas Carr | ▼ Sell | Tax Withholding | 16,611 | $25K | 11/1/2023 |
| Diem Michael Craig | ▼ Sell | Tax Withholding | 20,763 | $31K | 11/1/2023 |
| Diem Michael Craig | ▲ Buy | Grant | 151,058 | $0 | 5/15/2023 |
| Douglas Carr | ▲ Buy | Grant | 120,846 | $0 | 5/15/2023 |
| Borges Luis | ▲ Buy | Option Exercise | 7,452 | $8K | 4/3/2023 |
| Borges Luis | ▲ Buy | Option Exercise | 220,930 | $228K | 3/23/2023 |
| Borges Luis | ▼ Sell | Open Market | 15,597 | $55K | 3/23/2023 |
| Borges Luis | ▲ Buy | Option Exercise | 65,698 | $68K | 3/22/2023 |
| Borges Luis | ▼ Sell | Open Market | 65,698 | $245K | 3/22/2023 |
| Borges Luis | ▼ Sell | Open Market | 63,616 | $240K | 3/21/2023 |
| Borges Luis | ▲ Buy | Option Exercise | 63,616 | $66K | 3/21/2023 |
| Farid Adrienne | ▲ Buy | Grant | 21,875 | $0 | 2/2/2023 |
| Diem Michael Craig | ▲ Buy | Grant | 21,875 | $0 | 2/2/2023 |
| Diem Michael Craig | ▲ Buy | Grant | 21,875 | $0 | 2/2/2023 |
| Douglas Carr | ▲ Buy | Grant | 7,500 | $0 | 2/2/2023 |
| Douglas Carr | ▲ Buy | Grant | 7,500 | $0 | 2/2/2023 |
| Borges Luis | ▲ Buy | Grant | 21,875 | $0 | 2/2/2023 |
| Borges Luis | ▲ Buy | Grant | 21,875 | $0 | 2/2/2023 |
| Farid Adrienne | ▲ Buy | Grant | 21,875 | $0 | 2/2/2023 |
| Versant Venture Capital VI, L.P. | ▼ Sell | Open Market | 550,000 | $7.2M | 8/9/2022 |
| Versant Venture Capital VI, L.P. | ▼ Sell | Other | 364,800 | $0 | 8/9/2022 |
| Versant Venture Capital VI, L.P. | ▼ Sell | Other | 178,996 | $0 | 1/31/2022 |
| Versant Venture Capital VI, L.P. | ▼ Sell | Other | 371,004 | $0 | 12/23/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Century Therapeutics faces competitive pressure on key strategy
A recent analysis suggests that competitors are taking steps to reduce the risks associated with Century Therapeutics' primary business focus. This development is relevant as it may impact the company's market position and future prospects. The stock is currently trading near its support levels, reflecting ongoing uncertainty in the market.
Century Therapeutics faces competitive pressure on key strategy. A recent analysis suggests that competitors are taking steps to reduce the risks associated with Century Therapeutics' primary business focus. This development is relevant as it may impact the company's market position and future prospects. The stock is currently trading near its support levels, reflecting ongoing uncertainty in the market.